HC Wainwright Reiterates Buy Rating for Daré Bioscience (NASDAQ:DARE)

HC Wainwright reaffirmed their buy rating on shares of Daré Bioscience (NASDAQ:DARE) in a report published on Tuesday,Benzinga reports. They currently have a $12.00 price target on the biotechnology company’s stock. HC Wainwright also issued estimates for Daré Bioscience’s FY2029 earnings at $15.48 EPS.

Daré Bioscience Trading Up 0.7 %

DARE stock opened at $2.93 on Tuesday. The company has a market capitalization of $25.49 million, a P/E ratio of -4.96 and a beta of 1.38. The business has a 50 day simple moving average of $3.04 and a 200-day simple moving average of $3.28. Daré Bioscience has a twelve month low of $2.67 and a twelve month high of $7.56.

Daré Bioscience (NASDAQ:DARE) last issued its quarterly earnings results on Monday, March 31st. The biotechnology company reported ($0.64) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.66) by $0.02. The business had revenue of ($0.06) million for the quarter, compared to analyst estimates of $1.00 million. Research analysts predict that Daré Bioscience will post -0.49 EPS for the current fiscal year.

Institutional Trading of Daré Bioscience

Hedge funds have recently added to or reduced their stakes in the stock. AMH Equity Ltd raised its stake in shares of Daré Bioscience by 50.0% during the fourth quarter. AMH Equity Ltd now owns 150,000 shares of the biotechnology company’s stock worth $468,000 after purchasing an additional 50,000 shares during the last quarter. Jane Street Group LLC purchased a new position in Daré Bioscience in the 4th quarter valued at $52,000. Renaissance Technologies LLC increased its stake in Daré Bioscience by 6.7% in the 4th quarter. Renaissance Technologies LLC now owns 68,695 shares of the biotechnology company’s stock valued at $214,000 after buying an additional 4,300 shares during the period. Finally, Geode Capital Management LLC raised its position in Daré Bioscience by 4.0% during the 4th quarter. Geode Capital Management LLC now owns 92,653 shares of the biotechnology company’s stock worth $289,000 after buying an additional 3,593 shares during the last quarter. 6.70% of the stock is owned by institutional investors and hedge funds.

Daré Bioscience Company Profile

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.